Ardelyx (US:ARDX) — Company Overview, News & Financial Data
Ardelyx is dedicated to developing medicines for kidney and cardiovascular diseases, addressing significant unmet medical needs.
About Ardelyx
Ardelyx (NASDAQ:ARDX) specializes in discovering, developing, and commercializing innovative medicines to improve treatment for people with kidney and cardiovascular diseases. The company is focused on addressing unmet medical needs, particularly in the realms of cardiorenal diseases, a term that refers to heart conditions that are caused or worsened by kidney problems. Ardelyx’s commitment is towards projects that leverage its unique understanding of kidney function and the mechanisms behind these conditions. Its main objectives include advancing its lead drug candidates through clinical trials, securing regulatory approvals, and establishing strategic partnerships to ensure the broadest possible access to its therapies.
Snapshot
Operations
Products and/or services of Ardelyx
- Ibsrela: A prescription medicine used for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
- Xphozah: An FDA-approved treatment for control of serum phosphorus in adults with chronic kidney disease on dialysis.
- RDX013: A potassium secretagogue in development for the potential treatment of hyperkalemia, a condition characterized by elevated potassium levels.
- RDX020: An investigational drug aimed at treating metabolic acidosis, a condition where there is too much acid in the body fluids.
- Tenapanor: In clinical testing for its ability to reduce abdominal pain and improve bowel habits in patients with irritable bowel syndrome.
- Research and Development: Focused on discovering and developing innovative treatments for gastrointestinal and cardio-renal diseases.
Ardelyx executive team
- Mr. Michael G. RaabPresident, CEO & Director
- Ms. Elizabeth A. Grammer Esq.General Counsel
- Dr. Laura A. Williams M.D., M.P.H.Chief Patient Officer & Interim Chief Medical Officer
- Mr. Mike KelliherChief Business Officer
- Ms. Sue HohenleitnerChief Financial Officer
- Mr. Joseph ReillySenior VP of Finance & Principal Accounting Officer
- Ms. Caitlin LowieVice President of Corporate Communications & Investor Relations
- Mr. James P. BradyChief Human Resources Officer
- Mr. Eric Duane FosterChief Commercial Officer
- Dr. John Bishop Ph.D.Chief Technical Operations Officer